Moderna's (MRNA) Underperform Rating Reaffirmed at Bank of America

Moderna (NASDAQ:MRNA - Get Free Report)'s stock had its "underperform" rating reiterated by research analysts at Bank of America in a research note issued on Tuesday, Marketbeat Ratings reports. They presently have a $41.00 price target on the stock. Bank of America's target price would suggest a potential downside of 1.23% from the company's current price.

Other equities analysts have also issued reports about the company. Oppenheimer lowered Moderna from an "outperform" rating to a "market perform" rating in a research note on Friday, September 13th. TD Cowen dropped their price objective on Moderna from $70.00 to $60.00 and set a "hold" rating on the stock in a research note on Friday, September 13th. HSBC upgraded Moderna from a "hold" rating to a "buy" rating and set a $58.00 price objective on the stock in a research note on Monday, November 18th. Wolfe Research started coverage on Moderna in a research note on Friday, November 15th. They issued an "underperform" rating and a $40.00 price objective on the stock. Finally, JPMorgan Chase & Co. dropped their price objective on Moderna from $59.00 to $45.00 and set an "underweight" rating on the stock in a research note on Tuesday, November 26th. Four research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Moderna presently has a consensus rating of "Hold" and a consensus target price of $79.50.

Moderna Stock Down 9.1 %

MRNA traded down $4.14 during trading on Tuesday, reaching $41.51. 10,464,516 shares of the stock traded hands, compared to its average volume of 4,974,040. The stock has a market cap of $15.97 billion, a price-to-earnings ratio of -7.39 and a beta of 1.58. Moderna has a fifty-two week low of $35.80 and a fifty-two week high of $170.47. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The stock's 50-day simple moving average is $49.84 and its two-hundred day simple moving average is $86.50.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The company had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. During the same period last year, the company earned ($1.39) earnings per share. The business's revenue was up 3.8% compared to the same quarter last year. As a group, equities research analysts expect that Moderna will post -9.32 EPS for the current year.

Insider Buying and Selling at Moderna

In other news, CFO James M. Mock sold 715 shares of the business's stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the transaction, the chief financial officer now directly owns 9,505 shares of the company's stock, valued at $571,440.60. The trade was a 7.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Shannon Thyme Klinger sold 1,418 shares of the business's stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the transaction, the insider now directly owns 19,717 shares in the company, valued at $843,690.43. The trade was a 6.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 3,379 shares of company stock valued at $158,195. 15.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Inspire Trust Co. N.A. boosted its holdings in shares of Moderna by 73.5% in the 3rd quarter. Inspire Trust Co. N.A. now owns 16,525 shares of the company's stock worth $1,104,000 after acquiring an additional 7,000 shares in the last quarter. Teachers Retirement System of The State of Kentucky lifted its holdings in Moderna by 1.4% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 287,887 shares of the company's stock worth $19,239,000 after buying an additional 3,978 shares in the last quarter. Toronto Dominion Bank lifted its holdings in Moderna by 23.7% during the 3rd quarter. Toronto Dominion Bank now owns 131,477 shares of the company's stock worth $8,787,000 after buying an additional 25,177 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Moderna by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company's stock worth $470,670,000 after buying an additional 178,115 shares in the last quarter. Finally, Groupama Asset Managment lifted its holdings in Moderna by 29.1% during the 3rd quarter. Groupama Asset Managment now owns 21,838 shares of the company's stock worth $1,459,000 after buying an additional 4,920 shares in the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.